Go offline with the Player FM app!
Making Sense of Antisense Oligonucleotides
Archived series ("Inactive feed" status)
When? This feed was archived on April 16, 2022 11:29 (). Last successful fetch was on February 08, 2022 17:50 ()
Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 244373763 series 1155727
How does a potential drug discovered in the lab ultimately end up in people? We tackle this question in the context of exciting gene-modifying therapies called antisense oligonucleotides (ASOs). In this episode, we speak with Dr. Tim Miller to break down the science behind ASOs and learn more about his work in finding a cure for a genetic form of amyotrophic lateral sclerosis (ALS).
This episode was written and produced by Nancy Cai, Devika Nair, and Arja Ray.
Music used in this episode: “Thannoid”, “Bundt”, “Lupi”, “Partly Sage”, “Beignet”, “Trailrunner”, “Game Hens”, “Lord Weasel”, “The Zeppelin”, “Dorica”, “Our Fingers Cold”, “Gaena” by Blue Dot Sessions
For more information about spinal muscular atrophy (SMA), check out the spinal muscular dystrophy association website: https://www.mda.org/disease/spinal-muscular-atrophy.
There is also this great animation that shows how the Spinraza (nusinersen) ASO works in the body: https://www.spinraza.com/en_us/home/taking/how-spinraza-works.html.
To read the results from the first ASO for Huntington’s disease, check out the New England Journal of Medicine article here: https://www.nejm.org/doi/full/10.1056/NEJMoa1900907?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed.
165 episodes
Archived series ("Inactive feed" status)
When? This feed was archived on April 16, 2022 11:29 (). Last successful fetch was on February 08, 2022 17:50 ()
Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 244373763 series 1155727
How does a potential drug discovered in the lab ultimately end up in people? We tackle this question in the context of exciting gene-modifying therapies called antisense oligonucleotides (ASOs). In this episode, we speak with Dr. Tim Miller to break down the science behind ASOs and learn more about his work in finding a cure for a genetic form of amyotrophic lateral sclerosis (ALS).
This episode was written and produced by Nancy Cai, Devika Nair, and Arja Ray.
Music used in this episode: “Thannoid”, “Bundt”, “Lupi”, “Partly Sage”, “Beignet”, “Trailrunner”, “Game Hens”, “Lord Weasel”, “The Zeppelin”, “Dorica”, “Our Fingers Cold”, “Gaena” by Blue Dot Sessions
For more information about spinal muscular atrophy (SMA), check out the spinal muscular dystrophy association website: https://www.mda.org/disease/spinal-muscular-atrophy.
There is also this great animation that shows how the Spinraza (nusinersen) ASO works in the body: https://www.spinraza.com/en_us/home/taking/how-spinraza-works.html.
To read the results from the first ASO for Huntington’s disease, check out the New England Journal of Medicine article here: https://www.nejm.org/doi/full/10.1056/NEJMoa1900907?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed.
165 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.